What is Prolia (denosumab)–associated osteonecrosis?
Prolia is a cancer-adjacent term people often use for denosumab, a drug that affects bone remodeling by blocking RANKL. A key concern linked to bone antiresorptives (including denosumab) is osteonecrosis of the jaw (ONJ), a condition where jawbone fails to heal after an injury or dental procedure. This is the form most often discussed with Prolia. [1]
What symptoms should people watch for?
People commonly report jaw-related symptoms that can include pain, swelling, exposed jawbone, loose teeth, or delayed healing after dental work. Symptoms can be subtle at first, so persistent jaw discomfort or non-healing after a dental procedure is a reason to contact a clinician promptly. [1]
Who is at higher risk of ONJ with Prolia?
Risk is generally higher in people with factors that impair healing and increase jaw stress, such as invasive dental procedures (especially tooth extractions), poor oral health/dental infections, and longer or higher-intensity exposure to antiresorptive therapy. Clinicians also consider cancer-related dosing and other systemic risk factors when estimating risk. [1]
What dental care reduces risk before and during Prolia?
A common strategy is to do a dental evaluation before starting therapy and to complete needed invasive dental work when appropriate, then maintain consistent oral hygiene and regular dental follow-up during treatment. If a patient needs an extraction or other invasive procedure, the treating dentist and prescribing clinician coordinate the plan. [1]
Does Prolia cause osteonecrosis anywhere else besides the jaw?
The best-known association is osteonecrosis of the jaw (ONJ). “Osteonecrosis” in general can also refer to other conditions, but for Prolia/denosumab the dominant clinical concern people seek is ONJ. If you meant a different site (for example, hip osteonecrosis), share the location and your diagnosis wording. [1]
How is ONJ treated if it happens?
Treatment usually focuses on controlling infection/inflammation, improving oral hygiene, and supporting healing. Management can include antimicrobial rinses and symptomatic care, and in some cases surgical approaches depending on severity. The exact plan depends on how advanced the condition is and the patient’s cancer therapy context. [1]
Can people keep taking Prolia if they develop ONJ?
Whether to continue or hold denosumab depends on severity, clinical stability, cancer/osteoporosis risk, and how urgently other therapies are needed. Clinicians typically weigh the benefit of fracture or cancer-related skeletal risk reduction against the risk of worsening ONJ, and coordinate with dental specialists. [1]
Is there a difference between Prolia and Xgeva osteonecrosis risk?
Denosumab is used in different products and dosing schedules. Xgeva is commonly associated with oncology indications, while Prolia is used for osteoporosis and similar bone-loss conditions. Both can be linked to ONJ, but risk discussions often differ because treatment context and exposure patterns are not the same. [1]
When should you seek urgent care?
Seek urgent dental/oral medicine evaluation if you have exposed jawbone, rapidly increasing jaw swelling or pain, fever, pus, or symptoms after a recent extraction that are not improving. These can signal infection or more advanced ONJ requiring prompt assessment. [1]
---
Sources
[1] FDA. Prolia (denosumab): Important Safety Information—Osteonecrosis of the Jaw (ONJ). https://www.fda.gov/